Pfizer Corporation

The Brigham and Women's Hospital, Inc.

Wyeth

Genetics Institute, Inc.

Whitehead Institute for Biomedical Research

Edward Roland Lavallie

Lidia Mosyak

Lisa Anne Collins-Racie

Christopher John Corcoran

Geertruida Machteld Veldman

Lioudmila Tchistiakova

Kimberly Ann Marquette

Xiang-Yang Tan

Riyez Karim

John Adam Nowak

Juan C Almagro

Anthony Coyle

Stefano V Gulla

Eric M Bennett

Janet Elizabeth Buhlmann

Sreekumar R Kodangattil

Christine Huard

Steven A Greenberg

James Perry Hall

Madan Katragadda

Adam Reid Root

Divya Mathur

Chew Shun Chang

Gurkan Guntas

Lisa A Racie

Thomas John Van Blarcom

Javier Fernando Chaparro Riggers

Kathleen N Tomkinson

Chia-Yang Lin

Bethany Annis Freeman

Katy Evangelia Georgiadis

Janet E Paulsen

Hazel Sive

Tara K Crawford

Benjamin Sun

Janet Paulsen

Alison Jane Forgie

Andrea Rossi

Lioudmila Gennadievna Tchistiakova

Jame Perry Hall

The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFNβ). Such antibodies, or antigen-binding fragments thereof, are are useful for various therapeutic or diagnostic purposes.

Interferon beta antibodies and uses thereof

The present invention provides novel antibodies that specifically bind to GUCY2c and uses thereof in the treatment of cancer. The present invention further provides novel bispecific antibodies comprising such antibodies and uses thereof in the treatment of cancer.

Antibodies specific for GUCY2c and uses thereof

The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFN&#x3b2;). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes.

The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Antibody to GDF8 and uses thereof

The disclosure provides novel molecules related to growth and differentiation factor 8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8 associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

The present invention provides antagonizing antibodies that bind to glucagon receptor and methods of using same. The anti-glucagon receptor antibodies can be used therapeutically to lower glucose levels in blood, and can be in the prevention and/or treatment of glucose-related disorders, including diabetes, hyperglycemia, hyperinsulinemia, impaired fasting glucose, impaired glucose tolerance, dyslipidemia, or metabolic syndrome.

Anti-glucagon receptor antibodies and pharmaceutical compositions thereof

Truncated aggrecanase proteins and nucleotides sequences encoding them as well as processes for producing them are disclosed. Additionally, aggrecanases with amino acid mutations that lead to increased stability and expression levels in comparison with wild-type or native aggrecanases are also disclosed. Aggrecanases of the invention are especially useful for development of compositions for treatment of diseases such as osteoarthritis. Methods for developing inhibitors of the aggrecanase enzymes and antibodies to the enzymes for treatment of conditions characterized by the degradation of aggrecan are also disclosed.

Truncated aggrecanase molecules

Purified Frazzled proteins, including WG67-16, WG67-19 and WA628, and processes for producing them are disclosed. DNA molecules encoding the Frazzled proteins, including WG67-16, WG67-19 and WA628, are also disclosed. The proteins may be used in modulating the binding of Wnt genes to their receptor. They are useful in the modulation of cellular formation, growth, differentiation, proliferation and/or maintenance of a variety of adult and embryonic tissues and organs.

Frazzled nucleotide sequences and expression products

Growing community of inventors

Harvard, MA, United States of America

Edward Roland Lavallie